natgillin/translations-raw huggingface dataset:
Preferred permanent magnetic powder materials include cobalt, iron and their alloys, chromium dioxide, magnetic oxide spinels, magnetic garnets, magnetic ferrites including the hexaferrites such as calcium-, strontium-, and barium-hexaferrite (CaFe12O19, SrFe12O19, BaFe12O19, respectively), alnico alloys, samarium-cobalt (SmCo) alloys, and rare-earth-iron-boron alloys (such as NdFeB), as well as permanent-magnetic chemical derivatives based on these structure types and mixtures including them. 
Poželjni permanentno magnetski praškasti materijali uključuju sljedeće: kobalt, željezo 1 njihove legure, krom dioksid, magnetske oksid spinele, magnetske granate, magnetske ferite, uključujući heksaferite poput kalcij-, stroncij- i barij-heksaferita (CaFe;2O;9, STFe;2O;9, BaFe;20;9), alnico legure, legure samarij- kobalta (SmCo) i legure rijetka zemlja-željezo-bor (poput NdFeB), te permanentno magnetski kemijski derivati koji se temelje na navedenim vrstama struktura i mješavinama u kojima su uključene.
A compound according to claim 1 selected from the group consisting of 
Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koja se sastoji od sljedećih:
UL25, wherein said UL25 comprises the amino acid sequence set forth in SEQ ID NO: 5 or an immunogenic fragment thereof comprising at least 15 contiguous amino acids of SEQ ID NO: 5; and 
Smjesa iz patentnog zahtjeva 1 ili 2, naznačena time, što UL25 sadrži aminokiselinsku sekvencu navedenu u SEQ ID NO:5.
A method according to claim 1 further comprising the steps of: repositioning the plow bow-forward in a direction opposite the initial seabed path direction and on a second seabed path along one of the port and starboard sides of the initial seabed path; and propelling the plow along the second seabed path to cause the moldboards to clear boulders from the second seabed path and further from the first seabed path. 
Metoda u skladu s patentnim zahtjevom 1 koja dalje obuhvaća korake: repozicioniranja pluga (100) nagnuto naprijed u smjeru suprotnom od smjera početne putanje po morskom dnu i na drugu putanju po morskom dnu duž jedne od lijeve i desne strane početne putanje po morskom dnu; i pokretanja pluga duž druge putanje po morskom dnu da prouzrokuje da odgrnjače razgrnu kamenje sa druge putanje po morskom dnu i dalje od prve putanje po morskom dnu.
Package according to claim 6 or 7, characterized in that said one or more portions of fish in the solid form (10) have soft consistence due to swelling with saline solution. 
Pakiranje sukladno zahtjevu 6 ili 7, naznačeno time što jedna 1li više porcija ribe u čvrstom obliku (10) imaju meku konzistenciju zbog upijanja otopine soli.
The biomorphic hydroxyapatite scaffold according to claim 5, wherein, preferably when the wood is rattan, at least 25% of the total porosity, preferably between 25% and 50% of the total porosity of the scaffold is due to pores having a diameter ≤1 µm, preferably ≤ 0.1 µm, more preferably between 0.01 and 0.1 µm. 
Biomorfna hidroksiapatitna skela u skladu sa patentnim zahtjevom 5, pri čemu, poželjno kada je drvo ratan, najmanje 25% ukupne poroznosti, poželjno između 25% i 50% ukupne poroznosti skele je zbog pora koje imaju promjer ≤1 µm, poželjno ≤ 0.1 µm, poželjnije između 0.01 i 0.1 µm.
After a further 30 minutes, 1M aqueous NaOH (800 µL) is added, and the reaction is shaken mechanically for 105 minutes, then 1M aqueous HCl (800 µL) is added. 
Nakon daljnjih 30 minuta, doda se 1 M vodeni NaOH (800 ul) i reakcijsku smjesu se mehanički mućka 105 minuta i zatim se doda 1 M vodenu HCI (800 ul).
About 42 mg of the propylene glycol-glycerol mixture was applied to the substrate. 
Oko 42 mg smjese propilen-glikol-glicerol primjeni se na supstrat.
Example 7 Preparation of a Composite Material 
Primjer 7 - Priprava kompozitnog materijala
Y is a bivalent radical having the following meaning: 
Y je dvovalentni radikal koji ima sljedeće značenje: a)
Molecular weight: 296 g/mol Functionality: 1 
296 g/mol, funkcionalnost: 1, dobavljač:
observing the cross-cut surfaces in etched condition under an optical microscope with a magnification selected such that phase boundaries are distinguishable; 
Promatranje jetkane poprečno presječene površine optičkim mikroskopom s povećanjem prikladnim za uočavanjem granica faze;
The system of claim 14 wherein the bacteria is adapted to be effective as a forage inoculant. 
Sustav prema zahtjevu 14, naznačen time što je bakterija prilagođena da bude učinkovita kao inokulant za krupnu stočnu hranu.
from 10% to 40% by weight of a calcium receptor-active compound chosen from cinacalcet HCl and; 
PATENTNI ZAHTJEVI Farmaceutska smjesa koja sadrži (a) od 10% do 40% težinski smakalcet HCiI;
The aqueous agrochemical suspension according to claim 1, wherein the suspension is a composition and the amount of the at least one kind of alcohol selected from the group consisting of ethylene glycol, propylene glycol and glycerin is within a range of 5 to 60 parts by weight, the amount of the inorganic thickener is within a range of 4 to 30 parts by weight and the amount of the dispersant is within a range of 5 to 85 parts by weight, as opposed to 100 parts by weight of 2-(2,6-difluorophenyl)-4-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydrooxazole. 
Vodena agrokemijska suspenzija u skladu sa patentnim zahtjevom 1, gdje suspenzija je kompozicija 1 količina barem jedne vrste alkohola odabrane iz grupe koja se sastoji od etilen glikola, propilen glikola i glicerina je u okviru opsega od 5 do 60 dijelova po masi, količina neorganskog sredstva za zgušnjavanje je u okviru opsega od 4 do 30 dijelova po masi i količina dispergirajućeg sredstva je u okviru opsega od 5 do 85 dijelova po masi, za razliku od 100 dijelova po masi 2-(2,6-difluorofenil)-4-[4-(1,1-dimetiletil)-2-etoksifenil]-4,5-dihidrooksazola.
The security element according to claim 1 or 2, characterized in that the surface areas of the magnetic materials (4, 5) are equal in size. 
Sigurnosni element prema zahtjevu 1 ili 2, naznačen time što su površine magnetskih materijala (4, 5) jednake veličine.
Compounds of formula (1) may also be prepared by reacting a compound of formula (111) (wherein R1, R2 and R3 have the meanings defined in formula (1) and R6 is 2-hydroxy phenyl) with carbonyl dimidazole or thiocarbonyl diimidazole in a suitable solvent such as dichloromethane and subsequent reaction of the products this formed with the amine HNR4R5. 
O (111) (gdje Ri, R, i Rz znače kao što je definirano za formulu (1), a R4 je 2-hidroksifenil) s karbonildiimidazolom ili tiokarbonildiimidazolom, u pogodnom otapalu, poput diklormetana, te naknadnom reakcijom tako dobivenih produkata s aminom HNRRs.
The conjugate of claim 26, wherein the brain effector entity is selected from the group consisting of proteins, polypeptides and peptides. 
Konjugat prema zahtjevu 21, naznačen time, da je entitet moždanog efektora odabran iz skupine koja se sastoji od proteina, polipeptida i peptida.
PCT International Application No. 
(86) Broj međunarodne prijave:
The compound of claim 1, which is selected from the group consisting of the following compounds: 
Spoj prema patentnom zahtjevu 3, naznačen time što je odabran iz skupine koja sadrži slijedeće spojeve:
In one embodiment, the PEG or composition comprising PEG, as described herein, is administered topically to one or more sites exhibiting an active viral infection (for example, a cold sore or other physical symptom of a “breakout” indicative of an active viral infection) or to a site where there are no signs of an active infection but where active infection (e.g., recurrent breakouts) is known to occur, or is expected to occur. 
Polietilen glikol za uporabu prema bilo kojem zahijevu od 1 do 6, naznačen time, da se topikalna primjena vrši na jednom ili više mjesta koja su izložena aktivnoj virusnoj infekciji ili mjesta gdje više nema znakova aktivne infekcije, ali gdje se aktivna infekcija obično pojavljuje ili se očekuje njezina pojava.
The method of claim 4, wherein the at least one attenuated Salmonella or the least one inactivated Salmonella of the Salmonella B group is Salmonella Typhimurium. 
Cjepivo prema zahljevu 2, naznačeno time, da najmanje jedna neaktivirana Salmonella od Salmonella skupine B je Salmonella Typhimurium.
providing size reducing means (3) consisting of at least one series of parallel or intersecting sheets or wires that form at least one size reducing net located in said washing and separating container (1) and/or a size-reducing container (2), 
najmanje jednog ubrizgavanja sterilne otopine za ispiranje u komoru (101) za ispiranje koji sadrži materijal masti, iz spremnika (1) za ispiranje i odvajanje, čija komora (101) za ispiranje sadrži najmanje jedan element (104) za miješanje;
Liquid preparations of oral administration may be prepared in the form of syrups or suspensions, e.g. 
Tekuće kompozicije za oralno davanje mogu biti dobivene u obliku sirupa ili suspenzija, npr.
The preventative or therapeutic agent against infections in humans, animals and plants according to Claim 5, wherein the preventative or therapeutic agent against infections in humans, animals and plants according to Claim 5 contains an antibiotic. 
Preventivno ili terapijsko sredstvo protiv infekcija kod ljudi, životinja i biljaka u skladu s patentnim zahtjevom 3, gdje preventivno ili terapijsko sredstvo protiv infekcija kod ljudi, životinja i biljaka u skladu s patentnim zahtjevom 3 sadrži antibiotik.
The pharmaceutical composition may be adapted for oral, inhalation, parenteral, or topical use and may be administered to the patient in the form of tablets, capsules, aerosols, inhalants, suppositories, solutions, suspensions, or the like. 
Farmaceutski pripravak može se prilagoditi za oralnu, inhalacijsku, parenteralnu ili topikalnu upotrebu, te ga se može primijeniti na pacijentu u obliku tableta, kapsula, aerosola, inhalansa, supozitorija, otopina, suspenzija i slično.
In general, the disclosure there relates to an atomiser with a spring pressure of 5 to 60 MPa, preferably 10 to 50 MPa, on the fluid, with a volume per stroke of 10 to 50 ul, preferably 10 to 20 ul, most preferably about 15 ul per stroke, and particle sizes of up to 20 um, preferably 3 to 10 um. 
WO 91/1446 A1 i WO 97/12687 A1 odnose se na atomizer s tlačnom oprugom koja djeluje na fluid s 5 do 60 MPa, ponajprije 10 do 50 MPa, s volumenom po udaru od 10 do 50 ul, ponajprije 10 do 20 pi, ponajbolje pribl. 15 ml po udaru, i veličine čestica sve do 20 um, ponajprije 3 do 10 um.
represents a hydrogen atom, a methyl group or an ethyl group; or a pharmaceutically acceptable salt thereof. 
R3 predstavlja atom vodika, metilnu skupinu ili etilnu skupinu; ili njegova farmaceutski prihvatljiva sol.
A very particularly preferred embodiment of the invention provides an edging strip comprising a melt layer which is composed of at least one thermoplastic polyolefin or the polymer basis of which is composed of at least one thermoplastic polyolefin, and which optionally comprises other components, in particular in the form of pigments, fillers and additives. 
HR P20190228 T1 PATENTNI ZAHTJEVI Rubna traka, naročito za ploče za nameštaj, koja sadrži sloj taljevine, koji se sastoji od najmanje jednog lagano tekućeg poliolefina i proizvoljno od dodatnih komponenti, koje su odabrane iz skupine pigmenata, punila i aditiva, naznačena time što je najmanje jedan lagano tekući poliolefin odabran iz skupine
Compounds of the formula I as claimed in claims 1 to 11 in which U is S, 
Spojevi formule I u skladu s patentnim zahtjevima 1 do 11, gdje U je S,
Each of the elastomer materials of Examples 1-4 had an absorption coefficient a as defined above of ca. 1.5 mm−1 for laser light of wavelength 980 nm, measured using the method described above, i.e. 99% of such laser light at a power 8 W was absorbed in this thickness of the elastomer material. 
Svaki od elastomernih materijala iz primjera 1 - 4 imao je koeficijent apsorpcije a kao što je gore definirano od oko 1.5 mm"! za lasersko svijetlo valne duljine 980 nm, koji je bio izmjeren korištenjem postupka koji je gore opisan, to jest 99% takvog laserskog svijetla kod snage od 8 W je bilo apsorbirano u debljini elastomernog materijala.
Nos. 4,554,107 and 4,623,488 describe a method based on the technique of molecular distillation: fish oil, enriched in EPA and DHA, with a rather low yield (30%) because of the drastic experimental conditions, is obtained. 
US 4554107 i US 4623488 opisuju postupak koji se temelji na tehnici molekularne destilacije: dobiva se riblje ulje, obogaćeno EPA i DHA, s prilično niskim prinosom (30 %) zbog drastičnih eksperimentalnih uvjeta.
and the pharmaceutically acceptable salts of the aforementioned compounds. The compound of formula 1 ' wherein A, M,, Het, Hetaryl, R1 and R3 are defined according to claim 1, and the pharmaceutically acceptable salts of the aforementioned compounds. 
Spoj, naznačen time, da je predstavljen formulom 1’ gdje su A, M, Het, Hetaril, R1 i R3 definirani u skladu sa zahtjevom 1, i farmaceutski prihvatljive soli od gore spomenutih spojeva.
In one embodiment, the present composition comprises at least 50 wt.% fat droplets with a diameter of 5-25 micrometer based on total weight of fat. 
što najmanje 15%, težinski, masnih kapi ima promjer od 5-25 mikrometara, na osnovu ukupne težine masti za ishranu dojenčeta.
a 3' portion comprising a transposon end sequence, and a first tag comprising a first tag domain; applying a target DNA to the solid support under conditions whereby the target DNA is fragmented by the transposome complexes, and the 3' transposon end sequence of the first polynucleotide is transferred to a 5' end of at least one strand of the fragments; thereby producing an immobilized library of double-stranded fragments wherein at least one strand is 5'- tagged with the first tag. 
(b) stavljanju ciljane dvolančane DNA na čvrsti nosač u uvjetima u kojima se ciljanu DNA fragmentira transposomskim kompleksima, a terminalni slijed transposona na 3* kraju prvog polinukleotida se prebacuje na 5* kraj najmanje jednog lanca fragmenata; čime se dobiva imobiliziranu biblioteku dvolančanih fragmenata gdje je najmanje jedan lanac 5'-obilježeni prvim biljegom iz prvog slijeda, a najmanje jedan lanac je 5/- obilježeni prvim biljegom iz drugog slijeda.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbomene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) ciprodinil.
attaching, to the key of the data item (D1), the transaction identifier related to the transaction step, and 
- < Pridruživanje, na ključ podatkovne stavke (D1), pokazatelj prijenosa koji se odnosi na korak prijenosa, i
An aqueous solution of proteins is, with help of an eluent, passed through a solid phase or matrix composed of beads containing a range of pore sizes, chosen on the basis of the size of the target protein. 
Vodenu otopinu proteina se, uz pomoć eluensa, provodi kroz matriks ili čvrstu fazu koja se sastoji od kuglica koje imaju pore različitih veličina, odabranih na temelju veličine ciljnog proteina.
The antibody for use according to claim 23, wherein said muscuoskeletal disease or disorder is muscle atrophy, for example caused by a myopathy, such as myotonia, a congential myopathy, including nemalene myopathy, multi/minicore myopathy and myotubular (centronuclear) myopathy, mitochondrial myopathy, familial periodic paralysis, inflammatory myopathy, metabolic myopathy, such as caused by a glycogen or lipid storage disease, dermatomyositisis, polymyositis, inclusion body myositis, myositis ossificans, rhabdomyolysis and myoglobinurias; a dystrophy, such as Duchenne, Becker, myotonic, fascioscapulohumeral, Emery-Dreifuss, oculopharyngeal, scapulohumeral, limb girdle, Fukuyama, a congenital muscular dystrophy, or hereditary distal myopathy; osteoporosis; a bone fracture; short stature; dwarfism; prolonged bed rest; voluntary inactivity; or involuntary inactivity. 
Protutijelo za uporabu prema zahtjevu 23, naznačeno time, da se kod navedene muskulo-skeletne bolesti ili poremećaja radi o sljedećima: mišićna atrofija, primjerice uzrokovana miopatijom, kao što su miotonija, kongenitalna miopatija, uključujući nemalin-miopatiju, - multi-miopatiju, - minicore-miopatiju i miotubularnu = (centronuklearnu) = miopatiju, mitohondrijsku miopatiju, porodičnu periodičnu paralizu, upalnu miopatiju, metaboličku miopatiju, kao što je ona uzrokovana bolešću sakupljanja lipida ili glikogena, dermatomiositis, polimiositis, miositis ekstremiteta, osifikacijski miositis, rabdomiolizu i mioglobinurije; distrofija kao što su sljedeće: Duchenne, Becker, miotonska, fascioskapulohumeralna, Emery-Dreifuss, okulofaringealna, skapulohumeralna, pojasa udova, Fukuyama, kongenitalna mišićna distrofija, ili urođena distalna miopatija; osteoporoza; lom kosti; kratak stas; patuljatost; produženo trajanje odmora u krevetu; dobrovoljna neaktivnost i/ili nedobrovoljna neaktivnost.
a simulated powder x-ray diffraction pattern substantially as shown in Figure 1 and/or by an observed PXRD pattern substantially as shown in Figure 1; 
simulirani spektar difrakcije X-zraka praha, koji je u biti prikazan na Slici 1 i/ili opaženi spektar PXRD, kao što je prikazan na Slici 1;
Co-initiators are often added in order to conduct the initiation at room temperature. 
Ko-inicijatori su često dodani da se izvede inicijacija pri sobnoj temperaturi.
allowing for the coagulant to coagulate some of the foam for a controlled period so that an underside of the layer of foam polymeric material, which is closest to the substrate, coagulates to form a coagulated layer and an outer part of the foam layer does not coagulate and forms an uncoagulated layer; 
puštanja da koagulans koagulira dio pjene kroz kontrolirani period, tako da donja strana sloja pjenastog polimernog materijala, najbliža podlozi, koagulira kako bi se dobilo koagulirani sloj, dok vanjski dio pjenastog sloja ne koagulira i tvori nekoagulirani sloj;
at least one of (i) a pressure lowering agent selected from ACE-inhibitors, ARBs and CCBs, and/or (ii) a cholesterol lowering agent selected from statin derivatives, or any pharmaceutically acceptable salt and ester thereof, and 
[image] najmanje jedno od (i) sredstvo za smanjenje tlaka odabrano od ACE-inhibitora, od sredstava ARB i CCB, i/ili (ii) sredstvo za sniženje kolesterola odabrano od derivata statina, ili njihova bilo koja farmaceutski prihvatljiva sol i njihov takav ester, i
The pharmaceutical composition according to claim 9, further comprising one or more of the following: the filler microcrystalline cellulose, the lubricant magnesium stearate or sodium stearyl fumarate and the glidant colloidal anhydrous silica. 
Farmaceutski sastav prema zahtjevu 2, naznačen time, da nadalje obuhvaća jedno ili više od sljedećih sredstava: punilo mikrokristalna celuloza, mazivo magnezijev stearat ili natrijev stearil-fumarat i klizno sredstvo koloidni bezvodni silicijev dioksid.
is H or NH2; and R7 are each independently selected from H, C1-6alkyl and (CH2)jC3-7cycloalkyl; or R6 and R7, together with the nitrogen atom to which they are bound, form a 4, 5 or 6 membered heterocyclic group; R8 is H; 
R' je H ili NH2; svaki od R* i R/ je neovisno odabran od sljedećih: H, C,salkil i (CH2);Csscikloalkil; ili R. i R' zajedno s atomom dušika na kojega su vezani, tvore 4-članu, 5-članu ili 6-članu heterocikličku skupinu;
Suitable carriers or excipients are well known in the art. 
Pogodne podloge ili pomoćne tvari dobro su poznate u struci.
wherein Z1 is O or S and R5 is optionally substituted phenyl, or a salt thereof. 
ČH.R. iili gdje Zije Oili Si Rs je po izboru supstituirani fenil, ili njihovih soli.
The pharmaceutical composition of claim 3 further comprising an additional anticancer agent. 
Farmaceutski pripravak koja sadrži spoj sukladno patentnom zahtjevu 3 koji dodatno sadrži dodatno antikancerogeno sredstvo.
The apparatus of paragraph 4, wherein the drug comprises nicotine. The apparatus of paragraph 1, wherein the first release device is configured to vaporize or gasify the first substance associated with the first cartridge. 
E-cigareta (100) sukladno patentnom zahtjevu 1, naznačena time što je uređaj za prvo oslobađanje (118) konfiguriran za isparavanje ili uplinjavanje prve tvari povezane s prvim spremnikom (114).
allowing the plastic material to cure; 
- < omogućavanje skrućivanja plastičnog materijala;
In a further aspect, the present invention provides a pharmaceutical composition comprising a mixture of effective amounts of (A) as herein before defined and (B) as herein before defined, optionally together with a pharmaceutically acceptable carrier. 
U daljnjem aspektu predmetni izum daje farmaceutski sastav koji sadrži smjesu učinkovitih količina (A) kako je ovdje prije definirano i (B) kako je ovdje prije definirano, po izboru zajedno s farmaccutski prihvatljivim nosiocem.
The method of claim 8, wherein the agent for treatment of dyslipidemia is a statin, a fibrate, a niacin or a cholesterol absorption inhibitor. 
(d) sredstvo za liječenje dislipidemije je statin, fibrat, niacin i/ili inhibitor apsorpcije kolesterola.
10M Aqueous sodium hydroxide (13 ml) was added whilst stirring, the mixture was then stirred at room temperature until all the solids were dissolved. 
Doda se 10 M vodena otopina natrijevog hidroksida (13 ml) uz miješanje, a smjesu zatim miješa na sobnoj temperaturi dok se sve krutine ne otope.
The term “alkyl” refers to a saturated or unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms. 
"alkil" označava zasićeni ugljikovodični lanac koji može biti ravni lanac ili razgranati lanac, koji sadrži naznačeni broj atoma ugljika;
In the embodiment shown, simultaneous to the rotation of the rotary machine and rotating platform 6, the support shaft 7 rotates around the first axis A. The support shaft 7 can be rotated by an electric motor 11 integrally secured to rotating platform 6 . 
U isto vrijeme, nosiva osovina 7 koja je dio jedinice za rukovanje 4 obavlja rotaciju oko prve osi A pomoću elektromotora 11, koji je učvršćen na platformu 6 kao njezin sastavni dio.
The oral dosage form of any one of claims 1 to 4, wherein R1 is optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heterocyclyl. 
Spoj patentnog zahtjeva 4, gdje je R1 opcionalno supstituiran alkilom, opcionalno supstituiran cikloalkilom, ili opcionalno supstituiran heterociklilom.
introducing a nucleic acid molecule comprising at least one mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter according to any one of claims 1 to 4 and at least one nucleic acid encoding a protein (peptide) or a functional nucleic acid and a marker resistance gene, wherein said promoter and said nucleic acid are operably linked together forming a single- or multi-copy expression cassette or a vector comprising said nucleic acid molecule into a cell, 
Postupak izolacije prvorazredne ekspresije klonova, naznačen time, da sadrži sljedeće korake: a) uvođenje molekule nukleinske kiseline koja sadrži najmanje jednu mutaciju promotora alkoholne oksidaze 1 mutantne Pichia pastoris (AOX1) prema bilo kojem zahtjevu od 1 do 4 i najmanje jednu nukleinsku kiselinu koja kodira protein (peptid) ili funkcionalnu nukleinsku kiselinu i marker otpornosti gena, pri čemu su
selecting one or more amino acid positions within the VH framework residues, the VL framework residues or the VH and VL framework residues for mutation; and 
A odabir jedne ili više pozicija aminokiselina unutar rezidua iz domene Ver, rezidua iz domene Vr ili Vyg te rezidua iz domene Vr za mutaciju; i B
The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. 
Uvjeti deprotekcije za gore navedene skupine naizbježno će varirati u ovisnosti o izboru zaštitne skupine.